The program gives the winning company one year of access to KI Innovation’s incubator in Stockholm, including facilities, an incubator program and business coaching. In addition, the company receives support from AbbVie’s global network of researchers and experts.

“Collaborations with international pharmaceutical companies are crucial for new ideas to grow into solutions that really make a difference for patients. This collaboration gives us further opportunities to strengthen our offering to startups working with advanced drug development,” says Johan Weigelt, CEO of KI Innovations.

Five therapeutic areas

Golden Ticket is aimed at companies conducting research within AbbVie’s five therapeutic areas: immunology, oncology, neurology, ophthalmology, and aesthetics.

The Scandinavian Golden Ticket program offers one year incubation at KI Innovations with access to laboratories and office space in the heart of Hagastaden, mentorship and business advice from KI Innovations’ experienced business coaches, tailored support from AbbVie through international researchers and mentors, and exclusive access to both organizations’ networks, opening up opportunities for future collaborations.

The application period for startups that want to participate in the program will open shortly.